Abiomed, Inc. (NASDAQ:ABMD)
Stock Price:
$381.02
+0.23
(0.06%)
Updated
Dec 21, 2022 09:00 PM GMT+0000
Overview
Financials
Statistics
Profile
Chart
| Market Cap | 17.18B |
|---|---|
| Revenue | 1.07B |
| Gross Profit | 873.51M |
| Shares Out | 45.09M |
| EPS (ttm) | 5.8 |
| PE Ratio | 0.0000 |
| Forward PE | 0.0000 |
| Dividend Rate (ttm) | 0.0000 |
| Dividend Yield | 0.0000 |
| Trading Day | Dec 21 |
|---|---|
| Last Price | $381.02 |
| Previous Close | $380.79 |
| Change ($) | 0.23 |
| Change (%) | 0.06% |
| Day's Open | 380.79 |
| Day's Range | Market Closed |
| Day's Volume | 0 |
| 52 Week Range | 0 - 0 |
About Abiomed, Inc.
Abiomed Europe GmbH, Aachen / Germany, as affiliate of Abiomed Inc. headquartered in Danvers, Massachusetts, USA, is a leading medical technology company in the field of circulatory support.
Its products aim to enable heart recovery by improving blood circulation and/or heart pump function.
News
Quick info
Country
United States
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Employees
1,725
CEO
Michael Minogue
Address
22 Cherry Hill Dr
Danvers
Massachusetts
01923-2575
Danvers
Massachusetts
01923-2575
Phone
19787775410
Website
www.abiomed.com
Ticker Symbol
ABMD
Exchange
NASDAQ Stock Exchange
Reporting Currency
USD
Abiomed, Inc. income statements (2022) (USD)
| August 2022 | August 2022 | May 2022 | February 2022 | |
|---|---|---|---|---|
| Total Revenue | 277.15M | 277.15M | 1.03B | 261.18M |
| Cost of Revenue | 52.63M | 52.63M | 188.16M | 47.63M |
| Gross Profit | 224.52M | 224.52M | 843.60M | 213.55M |
| Research & Development | 40.48M | 40.48M | 163.40M | 40.87M |
| Selling General & Admin | 118M | 118M | 423.49M | 107.62M |
| Operating Expense | 211.10M | 211.10M | 775.05M | 196.11M |
| Operating Income | 66.05M | 66.05M | 256.71M | 65.06M |
| Other Income Expense Net | 0 | 0 | 0 | 0 |
| EBIT | 66.05M | 66.05M | 256.71M | 65.06M |
| Interest Income | 0 | 0 | 0 | 0 |
| Pretax Income | 69.82M | 69.82M | 190.56M | 57.88M |
| Income Tax | 15.27M | 15.27M | 54.06M | 12.13M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | 54.55M | 54.55M | 136.51M | 45.75M |
| Net Income Basic | 54.55M | 54.55M | 136.51M | 45.75M |
Abiomed, Inc. income statements (2021) (USD)
| October 2021 | August 2021 | May 2021 | February 2021 | |
|---|---|---|---|---|
| Total Revenue | 248.14M | 252.59M | 847.52M | 231.66M |
| Cost of Revenue | 43.89M | 45.19M | 161.91M | 41.11M |
| Gross Profit | 204.26M | 207.40M | 685.62M | 190.55M |
| Research & Development | 41.04M | 37.71M | 121.88M | 33M |
| Selling General & Admin | 102.78M | 103.48M | 334.18M | 86.20M |
| Operating Expense | 187.71M | 186.38M | 617.97M | 160.31M |
| Operating Income | 60.44M | 66.21M | 229.56M | 71.35M |
| Other Income Expense Net | 0 | 0 | 0 | 0 |
| EBIT | 60.44M | 66.21M | 229.56M | 71.35M |
| Interest Income | 0 | 0 | 0 | 0 |
| Pretax Income | 67.27M | -9.35M | 288.22M | 80.74M |
| Income Tax | 10.32M | 17.18M | 62.70M | 18.87M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | 56.95M | -26.53M | 225.53M | 61.87M |
| Net Income Basic | 56.95M | -26.53M | 225.53M | 61.87M |
Abiomed, Inc. income statements (2020) (USD)
| November 2020 | September 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|---|
| Total Revenue | 209.76M | 209.76M | 164.85M | 206.66M | 206.66M |
| Cost of Revenue | 38.74M | 38.74M | 35.98M | 39.37M | 39.37M |
| Gross Profit | 171.03M | 171.03M | 128.87M | 167.29M | 167.29M |
| Research & Development | 30.53M | 30.53M | 25.56M | 25.06M | 25.35M |
| Selling General & Admin | 79.17M | 79.17M | 67.54M | 83.89M | 83.89M |
| Operating Expense | 148.43M | 148.43M | 129.08M | 148.32M | 148.61M |
| Operating Income | 61.34M | 61.34M | 35.77M | 58.34M | 58.05M |
| Other Income Expense Net | 0 | 11.58M | 25.31M | -19.03M | -18.74M |
| EBIT | 61.34M | 61.34M | 35.77M | 58.34M | 58.05M |
| Interest Income | 0 | N.A | N.A | N.A | N.A |
| Pretax Income | 72.92M | 72.92M | 61.08M | 39.31M | 39.31M |
| Income Tax | 10.70M | 10.70M | 16.49M | 7.52M | 7.52M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Net Income | 62.21M | 62.21M | 44.59M | 31.80M | 31.80M |
| Net Income Basic | 62.21M | 62.21M | 44.59M | 31.80M | 31.80M |
Abiomed, Inc. income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | 221.58M | 204.97M | 207.67M | 207.08M |
| Cost of Revenue | 40M | 34.87M | 37.07M | 34.85M |
| Gross Profit | 181.59M | 170.11M | 170.59M | 172.23M |
| Research & Development | 25.86M | 24.27M | 24.15M | 26.56M |
| Selling General & Admin | 85.67M | 85.96M | 86.08M | 81.30M |
| Operating Expense | 151.53M | 145.10M | 147.30M | 142.70M |
| Operating Income | 70.06M | 59.88M | 60.37M | 64.38M |
| Other Income Expense Net | 26.96M | -42.52M | 42.77M | 34.15M |
| EBIT | 70.06M | 59.88M | 60.37M | 64.38M |
| Interest Income | N.A | N.A | N.A | N.A |
| Pretax Income | 97.02M | 17.36M | 103.14M | 98.53M |
| Income Tax | 27.80M | 4.29M | 14.22M | 24.57M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | 69.22M | 13.07M | 88.92M | 73.96M |
| Net Income Basic | 69.22M | 13.07M | 88.92M | 73.96M |
Abiomed, Inc. income statements (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Total Revenue | 200.56M | 181.78M | 180.01M | 174.44M |
| Cost of Revenue | 34.02M | 29.85M | 30.85M | 30.10M |
| Gross Profit | 166.54M | 151.93M | 149.16M | 144.34M |
| Research & Development | 23.71M | 22.56M | 21.43M | 21.20M |
| Selling General & Admin | 80.22M | 78.90M | 81.14M | 75.50M |
| Operating Expense | 137.96M | 131.30M | 133.42M | 126.80M |
| Operating Income | 62.61M | 50.48M | 46.59M | 47.63M |
| Other Income Expense Net | 1.90M | 1.35M | 1.90M | 873K |
| EBIT | 62.61M | 50.48M | 46.59M | 47.63M |
| Interest Income | N.A | N.A | N.A | N.A |
| Pretax Income | 64.51M | 51.83M | 48.49M | 48.51M |
| Income Tax | 19.65M | 1.71M | -41.58M | 11.66M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | 44.86M | 50.13M | 90.07M | 36.85M |
| Net Income Basic | 44.86M | 50.13M | 90.07M | 36.85M |
Abiomed, Inc. income statements (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Total Revenue | 154.02M | 132.82M | 132.47M |
| Cost of Revenue | 24.99M | 21.63M | 21.86M |
| Gross Profit | 129.03M | 111.20M | 110.61M |
| Research & Development | 17.12M | 18.97M | 16.67M |
| Selling General & Admin | 66.56M | 60.08M | 60.60M |
| Operating Expense | 108.67M | 100.68M | 99.13M |
| Operating Income | 45.35M | 32.14M | 33.34M |
| Other Income Expense Net | 300K | 341K | 449K |
| EBIT | 45.35M | 32.14M | 33.34M |
| Interest Income | N.A | N.A | N.A |
| Pretax Income | 45.65M | 32.48M | 33.79M |
| Income Tax | 32.21M | 7.98M | -3.58M |
| Minority Interest | 0 | 0 | 0 |
| Net Income | 13.45M | 24.50M | 37.37M |
| Net Income Basic | 13.45M | 24.50M | 37.37M |
Abiomed, Inc. balance sheet (2022) (USD)
| August 2022 | August 2022 | May 2022 | February 2022 | |
|---|---|---|---|---|
| Current Cash | 844.32M | 844.32M | 758.61M | 669.22M |
| Receivables | 91.10M | 91.10M | 90.61M | 88.95M |
| Inventory | 95.37M | 95.37M | 93.98M | 90.20M |
| Current Assets | 1.06B | 1.06B | 0.98B | 885.01M |
| Other Current Assets | 29.56M | 29.56M | 33.28M | 36.63M |
| Short Term Investments | 29.56M | 29.56M | 33.28M | 36.63M |
| Long Term Investments | 643.28M | 643.28M | 696.92M | 707.87M |
| Property/Plant Equipment | 198.48M | 198.48M | 202.49M | 196.88M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 38.17M | 38.17M | 39.52M | 40.28M |
| Tangible Assets (Net) | 1.42B | 1.42B | 1.39B | 1.32B |
| Other Assets | 10.07M | 10.07M | 6.12M | 6.34M |
| Total Assets | 1.70B | 1.70B | 1.67B | 1.59B |
| Accounts Payable | 34.80M | 34.80M | 35.35M | 32.07M |
| Other Current Liabilities | 105.97M | 105.97M | 103.11M | 94.73M |
| Total Current Liabilities | 140.76M | 140.76M | 138.46M | 126.80M |
| Total Liabilities | 167.44M | 167.44M | 170.07M | 159.94M |
| Long Term Debt | 0 | 0 | 0 | 0 |
| Current Long Term Debt | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 45.58M | 45.58M | 45.52M | 45.51M |
| Treasury Stock | -330.02M | -330.02M | -304.56M | -304.43M |
| Retained Earnings | 1.02B | 1.02B | 0.96B | 0.90B |
| Capital Surplus | N.A | N.A | N.A | N.A |
| Shareholder Equity | 1.54B | 1.54B | 1.50B | 1.43B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Abiomed, Inc. balance sheet (2021) (USD)
| October 2021 | August 2021 | May 2021 | February 2021 | |
|---|---|---|---|---|
| Current Cash | 650.56M | 523.03M | 583.70M | 486.45M |
| Receivables | 89.57M | 88.65M | 97.18M | 92.99M |
| Inventory | 85.99M | 83.66M | 81.06M | 82.45M |
| Current Assets | 871.49M | 729.87M | 787.97M | 693.69M |
| Other Current Assets | 45.37M | 34.54M | 26.03M | 31.80M |
| Short Term Investments | 45.37M | 34.54M | 26.03M | 31.80M |
| Long Term Investments | 658.55M | 728.52M | 706.39M | 734.74M |
| Property/Plant Equipment | 197.18M | 198.23M | 197.13M | 179.36M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 41.06M | 41.90M | 42.15M | 43.33M |
| Tangible Assets (Net) | 1.27B | 1.19B | 1.21B | 1.14B |
| Other Assets | 6.57M | 5.22M | 5.32M | 5.64M |
| Total Assets | 1.53B | 1.46B | 1.49B | 1.43B |
| Accounts Payable | 27.62M | 29.81M | 34.84M | 23.59M |
| Other Current Liabilities | 86.40M | 83.32M | 94.13M | 96.81M |
| Total Current Liabilities | 114.02M | 113.12M | 128.97M | 120.40M |
| Total Liabilities | 145.47M | 150.87M | 164.68M | 166.99M |
| Long Term Debt | 0 | 0 | 0 | 0 |
| Current Long Term Debt | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 45.44M | 45.31M | 45.25M | 45.20M |
| Treasury Stock | -300.16M | -297.62M | -288.03M | -287.9M |
| Retained Earnings | 858.44M | 801.48M | 828.01M | 771.15M |
| Capital Surplus | N.A | N.A | N.A | N.A |
| Shareholder Equity | 1.38B | 1.31B | 1.33B | 1.26B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Abiomed, Inc. balance sheet (2020) (USD)
| November 2020 | September 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|---|
| Current Cash | 533.08M | 202.24M | 214.83M | 192.34M | 192.34M |
| Receivables | 80.91M | 80.91M | 82.08M | 84.65M | 84.65M |
| Inventory | 83.21M | 83.21M | 89.28M | 90.09M | 90.09M |
| Current Assets | 716.62M | 716.62M | 619.69M | 635.86M | 635.86M |
| Other Current Assets | 19.42M | 19.42M | 20.96M | 18.01M | 18.01M |
| Short Term Investments | 19.42M | 330.84M | 212.54M | 250.78M | 250.78M |
| Long Term Investments | 611.35M | 202.61M | 289.44M | 306.03M | 207.80M |
| Property/Plant Equipment | 175.58M | 175.58M | 182.02M | 176.69M | 164.93M |
| Good Will | N.A | N.A | N.A | N.A | N.A |
| Intangible Assets | 42.90M | 42.90M | 46.32M | 19.01M | 14.91M |
| Tangible Assets (Net) | 1.06B | 1.10B | 1.03B | 1.03B | 1.03B |
| Other Assets | 10.04M | 82.59M | 4.38M | 3.56M | 117.66M |
| Total Assets | 1.33B | 1.33B | 1.25B | 1.22B | 1.22B |
| Accounts Payable | 21.73M | 21.73M | 27.75M | 32.77M | 32.77M |
| Other Current Liabilities | 83.48M | 83.48M | 56.55M | 73.80M | 99.11M |
| Total Current Liabilities | 105.21M | 105.21M | 110.38M | 131.89M | 131.89M |
| Total Liabilities | 145.57M | 145.57M | 147.66M | 151M | 151M |
| Long Term Debt | 0 | N.A | 8.37M | 8.55M | N.A |
| Current Long Term Debt | 0 | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 767.98M | 45.19M | 45.04M | 45.01M | 45.01M |
| Treasury Stock | -287.65M | 287.65M | 286.58M | 265.41M | 265.41M |
| Retained Earnings | 709.28M | 709.28M | 647.07M | 602.48M | 602.48M |
| Capital Surplus | N.A | 767.53M | 749.44M | 739.13M | 739.13M |
| Shareholder Equity | 1.18B | 1.18B | 1.10B | 1.07B | 1.07B |
| Other Liabilities | N.A | N.A | N.A | N.A | N.A |
Abiomed, Inc. balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 117.97M | 150.28M | 101.05M | 121.02M |
| Receivables | 100.99M | 94.32M | 86.21M | 90.81M |
| Inventory | 91.19M | 90.30M | 87.73M | 80.94M |
| Current Assets | 636.58M | 647.43M | 677.37M | 677.20M |
| Other Current Assets | 16.85M | 17.50M | 16.76M | 13.75M |
| Short Term Investments | 309.57M | 295.04M | 385.62M | 370.68M |
| Long Term Investments | 285.02M | 187.86M | 162.47M | 102.50M |
| Property/Plant Equipment | 173.52M | 170.15M | 164.89M | 145.01M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 15.21M | 14.80M | 15.41M | 18.01M |
| Tangible Assets (Net) | 1.01B | 0.96B | 0.97B | 0.90B |
| Other Assets | 6.68M | 5.10M | 5.15M | 1.54M |
| Total Assets | 1.20B | 1.12B | 1.13B | 1.05B |
| Accounts Payable | 31.57M | 31.74M | 29.69M | 32.19M |
| Other Current Liabilities | 69.81M | 62.40M | 55.08M | 61.55M |
| Total Current Liabilities | 126.26M | 112.23M | 100.20M | 106M |
| Total Liabilities | 149.75M | 132.89M | 122.47M | 117.46M |
| Long Term Debt | 9.51M | 9.44M | 11.29M | N.A |
| Current Long Term Debt | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 45.11M | 45.24M | 45.37M | 45.12M |
| Treasury Stock | 240.33M | 214.93M | 179.39M | 138.85M |
| Retained Earnings | 570.68M | 501.47M | 488.40M | 399.47M |
| Capital Surplus | 733.05M | 722.02M | 704.88M | 690.51M |
| Shareholder Equity | 1.05B | 0.99B | 1B | 0.94B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Abiomed, Inc. balance sheet (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Current Cash | 84.18M | 76.38M | 61.29M | 42.98M |
| Receivables | 88.22M | 74.20M | 67.51M | 70.01M |
| Inventory | 71.81M | 63.66M | 55.78M | 50.20M |
| Current Assets | 628.73M | 561.60M | 497.30M | 494.27M |
| Other Current Assets | 10.55M | 13.30M | 13.49M | 11.81M |
| Short Term Investments | 373.98M | 334.06M | 299.23M | 319.27M |
| Long Term Investments | 40.80M | 22.30M | 6.89M | 50.10M |
| Property/Plant Equipment | 138.46M | 134.07M | 127.32M | 117.17M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 15.52M | 15.73M | 15.84M | 16.71M |
| Tangible Assets (Net) | 818.27M | 759.24M | 689.41M | 653.72M |
| Other Assets | 3.91M | 3.50M | 15.70M | 1.58M |
| Total Assets | 0.96B | 887.17M | 812.04M | 786.38M |
| Accounts Payable | 26.18M | 21.88M | 25.67M | 23.57M |
| Other Current Liabilities | 59.49M | 53.11M | 46.16M | 56.56M |
| Total Current Liabilities | 92.98M | 81.98M | 76.68M | 84.68M |
| Total Liabilities | 105.59M | 94.21M | 88.68M | 96.85M |
| Long Term Debt | N.A | N.A | N.A | N.A |
| Current Long Term Debt | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 45.06M | 45.04M | 44.88M | 44.38M |
| Treasury Stock | 138.29M | 136.74M | 134.67M | 67.08M |
| Retained Earnings | 325.51M | 280.65M | 230.52M | 140.46M |
| Capital Surplus | 676.17M | 660.13M | 637.97M | 619.91M |
| Shareholder Equity | 851.53M | 792.95M | 723.36M | 689.52M |
| Other Liabilities | N.A | N.A | N.A | N.A |
Abiomed, Inc. balance sheet (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Current Cash | 50.50M | 44.54M | 43.97M |
| Receivables | 64.86M | 57.33M | 53.56M |
| Inventory | 46.89M | 40.63M | 36.93M |
| Current Assets | 422.20M | 370.17M | 350.92M |
| Other Current Assets | 9.19M | 9.01M | 9.02M |
| Short Term Investments | 250.75M | 218.66M | 207.44M |
| Long Term Investments | 49.49M | 55.95M | 37.67M |
| Property/Plant Equipment | 107.98M | 97.70M | 92.80M |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | 16.24M | 16.02M | 15.49M |
| Tangible Assets (Net) | 597.67M | 570.55M | 533.85M |
| Other Assets | 13.69M | 13.69M | 8.69M |
| Total Assets | 719.60M | 694.65M | 652.22M |
| Accounts Payable | 21.99M | 16.67M | 12.78M |
| Other Current Liabilities | 48.75M | 41.67M | 42.28M |
| Total Current Liabilities | 75.35M | 63.36M | 59.01M |
| Total Liabilities | 87.12M | 89.77M | 85.17M |
| Long Term Debt | N.A | 15.11M | 15.33M |
| Current Long Term Debt | N.A | 851K | 829K |
| Minority Interest | 0 | 0 | 0 |
| Common Stock | 44.27M | 44.20M | 44.08M |
| Treasury Stock | 66.62M | 66M | 64.57M |
| Retained Earnings | 103.61M | 90.16M | 65.66M |
| Capital Surplus | 605.70M | 592.08M | 580.02M |
| Shareholder Equity | 632.48M | 604.89M | 567.04M |
| Other Liabilities | N.A | N.A | N.A |
Abiomed, Inc. cash flow (2022) (USD)
| November 2022 | August 2022 | |
|---|---|---|
| Net Income | 106.13M | 54.55M |
| Depreciation | 6.72M | 6.62M |
| Changes in Receivables | 94.48M | 91.10M |
| Changes in Inventories | 102.24M | 95.37M |
| Cash Change | 820.37M | 844.32M |
| Cash Flow | 13.42M | 68.10M |
| Capital Expenditures | -5.61M | -6.78M |
| Investments | N.A | N.A |
| Investing Activity (other) | N.A | N.A |
| Total Investing Cash Flows | 101.57M | 8.11M |
| Dividends Paid | N.A | N.A |
| Net Borrowings | -866.09M | -873.88M |
| Other Financing Cash Flows | N.A | N.A |
| Cash Flow Financing | -110.18M | -23.94M |
| Exchange Rate Effect | N.A | N.A |
Abiomed, Inc. cash flow (2020) (USD)
| November 2020 | September 2020 | June 2020 | March 2020 | |
|---|---|---|---|---|
| Net Income | 62.21M | 62.21M | 44.59M | 31.80M |
| Depreciation | 11.14M | N.A | 5.48M | N.A |
| Changes in Receivables | -1.18M | 1.18M | 2.57M | 16.34M |
| Changes in Inventories | -6.08M | N.A | -211K | N.A |
| Cash Change | 105.72M | N.A | 22.49M | N.A |
| Cash Flow | 108.97M | N.A | 31.76M | N.A |
| Capital Expenditures | -19.55M | N.A | -10.04M | N.A |
| Investments | N.A | N.A | 77.75M | N.A |
| Investing Activity (other) | N.A | N.A | -2M | N.A |
| Total Investing Cash Flows | -81.31M | N.A | 13.76M | N.A |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | -552.5M | N.A | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A | -9.86M | N.A |
| Cash Flow Financing | -14.71M | N.A | -20.16M | N.A |
| Exchange Rate Effect | N.A | N.A | -2.87M | N.A |
Abiomed, Inc. cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | 69.22M | 13.07M | 88.92M | 73.96M |
| Depreciation | 5.38M | 4.69M | 4.37M | 4.19M |
| Changes in Receivables | -6.68M | -8.11M | 4.60M | -2.59M |
| Changes in Inventories | -1.06M | -4.97M | -7.24M | -10.66M |
| Cash Change | -32.31M | 49.23M | -19.97M | 36.84M |
| Cash Flow | 89.44M | 74.26M | 64.63M | 70.39M |
| Capital Expenditures | -8.85M | -12.36M | -12.25M | -8.54M |
| Investments | -75.45M | 25.28M | -30.89M | -14.92M |
| Investing Activity (other) | -13.1M | -5M | -2.8M | -12.3M |
| Total Investing Cash Flows | -97.41M | 7.93M | -45.94M | -35.75M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A | N.A | N.A |
| Cash Flow Financing | -24.95M | -31.73M | -39.28M | 3.02M |
| Exchange Rate Effect | 601K | -1.23M | 612K | -816K |
Abiomed, Inc. cash flow (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Net Income | 44.86M | 50.13M | 90.07M | 36.85M |
| Depreciation | 3.59M | 3.39M | 2.96M | 2.91M |
| Changes in Receivables | -14.01M | -6.69M | 2.50M | -5.15M |
| Changes in Inventories | -9.77M | -8.96M | -7.79M | -3.71M |
| Cash Change | 7.80M | 15.09M | 18.31M | -7.53M |
| Cash Flow | 74.62M | 60.56M | 46.63M | 56.40M |
| Capital Expenditures | -8.12M | -12.2M | -15.15M | -11.7M |
| Investments | -38.68M | -27.19M | 51.08M | -56.76M |
| Investing Activity (other) | -19.01M | -10.26M | -1.17M | N.A |
| Total Investing Cash Flows | -65.82M | -49.65M | 34.77M | -68.46M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A | N.A | N.A |
| Cash Flow Financing | -1.12M | 4.12M | -61.8M | 2.55M |
| Exchange Rate Effect | 118K | 62K | -1.29M | 1.98M |
Abiomed, Inc. cash flow (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Net Income | 13.45M | 24.50M | 37.37M |
| Depreciation | 2.78M | 2.86M | 2.46M |
| Changes in Receivables | -7.54M | -3.77M | 498K |
| Changes in Inventories | -6.61M | -4.06M | -1.3M |
| Cash Change | 5.97M | 566K | 4.93M |
| Cash Flow | 56.70M | 43.16M | 36.29M |
| Capital Expenditures | -26.49M | -7.87M | -9.8M |
| Investments | -25.22M | -35.51M | -7.4M |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | -51.71M | -43.39M | -17.21M |
| Dividends Paid | N.A | N.A | N.A |
| Net Borrowings | -140K | -193K | -184K |
| Other Financing Cash Flows | N.A | N.A | N.A |
| Cash Flow Financing | 1.61M | 1.14M | -14.43M |
| Exchange Rate Effect | -622K | -346K | 278K |
Abiomed, Inc. dividends (USD)
Total Valuation
Abiomed Inc. has a market cap or net worth of $17.18 billion. The enterprise value is $0.
Market Cap
17.18B
Enterprise Value
0
Important Dates
Earnings Date
n.a
Ex-Dividend Date
n.a
Share Statistics
Abiomed Inc. has 45.09 million shares outstanding.
Shares Outstanding
45.09M
Float
n.a
Valuation Ratios
The trailing PE ratio is 0.0000 and the forward PE ratio is 0.0000. Abiomed Inc.'s PEG ratio is 0.0000.
PE Ratio
n.a
Forward PE
n.a
PS Ratio
n.a
PB Ratio
n.a
PEG Ratio
n.a
Stock Price Statistics
The stock price has increased by 0.0000%. The beta is 0.0000, so Abiomed Inc.'s price volatility has been lower than the market average.
Beta (1Y)
0.0000
52-Week Price Change
0.0000%
50-Day Moving Average
0.00
200-Day Moving Average
0.00
Average Volume (30 Days)
0
Income Statement
In the last 12 months, Abiomed Inc. had revenue of $1.07 billion and earned $873.51 million in profits. Earnings per share was $5.8.
Revenue
1.07B
Gross Profit
873.51M
EBITDA
281.67M
Earnings per Share
5.8
About
Ticker Symbol
ABMD
Reporting Currency
USD
Key Executives
MINOGUE MICHAEL R
President, CEO, Chairman
Weber David M
Chief Operating Officer
BOLT WILLIAM J
SVP, QA and Regulatory Affairs
Bowen Robert
Chief Financial Officer
TOMSICEK MICHAEL JOHN
Vice President, CFO
Benali Karim
Chief Medical Officer
KUNG ROBERT T V
SVP, Chief Scientific Officer
Macdonald Christopher D
SVP Global Sales
Plano Matthew T.
VP, GLOBAL OPERATIONS
Flaherty Sheila Marie
VP, General Counsel